A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.

Marit M MelssenGina R PetroniKimberly A Chianese-BullockNolan A WagesWilliam W GroshNikole VarhegyiMark E SmolkinKelly T SmithNadejda V GaleassiDonna H DeaconElizabeth M GaughanCraig L Slingluff

Published in: Journal for immunotherapy of cancer (2019)

The clinical trial Mel58 was performed with IRB (#15781) and FDA approval and is registered with Clinicaltrials.gov on April 25, 2012 (NCT01585350). Patients provided written informed consent to participate. Enrollment started on June 24, 2012.

Keyphrases

toll like receptor
end stage renal disease
clinical trial
ejection fraction
inflammatory response
prognostic factors
peritoneal dialysis
immune response
patient reported outcomes
health insurance
open label
nuclear factor
patient reported
double blind